UROXATRAL
LOE Approachingalfuzosin hcl
NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
UROXATRAL (alfuzosin hcl) is post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Approved for signs, symptoms of benign prostatic hyperplasia, hypertension. First approved in 2003.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UROXATRAL (alfuzosin HCl) is an oral extended-release alpha-1 adrenoreceptor antagonist that selectively blocks receptors in the prostate, bladder neck, and prostatic urethra. It is indicated for benign prostatic hyperplasia (BPH) symptoms and hypertension by reducing smooth muscle tone in affected tissues.
$0.002BPart D
LOE ApproachingDeclining
Limited commercial growth potential with declining Part D claims; expect smaller brand team focused on maintenance and generic transition planning.
Mechanism of Action
post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
Indications (3)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.